ViGenCell Documents
Documents
0
Ticker
308080.KQ
ISIN
KR7308080001
ViGenCell SEC Filings
Type | Report | Date |
|---|---|---|
| No documents available | ||
ViGenCell Documents 2026
This page contains all official documents and SEC filings for ViGenCell stock (308080.KQ, ISIN: KR7308080001). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 0 documents are available. Data is updated regularly to provide investors with a complete overview of ViGenCell's regulatory filings.
ViGenCell Stock analysis
ViGenCell ViGenCell Inc is a biotechnology company based in Seoul, South Korea, operating within the Health Care sector. The company has 80 employees and completed its initial public offering (IPO) on August 25, 2021. ViGenCell focuses on research and development in natural science and engineering, with a particular emphasis on cell therapy technologies. The company develops and manufactures immuno-cancer cell therapy products and immunosuppressive cell therapy products. It also provides the Vitier platform, which is an antigen-specific killing T cell treatment, the Viranger platform for gamma delta T cell gene therapy, and the Vimedier platform-based technology for myeloid suppressor cell therapy derived from umbilical cord blood. ViGenCell is engaged in the research and development of new drugs targeting conditions such as acute myeloid leukemia (AML) and glioblastoma. The company's website is https://www.vigencell.com/. ViGenCell Inc is listed on the Korean stock market under the ticker 308080.KQ and has the ISIN KR7308080001. The company's headquarters are located in Seoul, South Korea.